GenVec/Parke-Davis BioByPass set to enter clinicals in early 1998; companies sign $100 mil. R&D agreement.
Executive Summary
GENVEC/PARKE-DAVIS BIOBYPASS TO BEGIN CLINICALS IN FIRST QUARTER 1998 in the initial indication of coronary artery disease. Patients in the trial will receive a one-time injection to the left ventricle of the gene therapy product, which delivers the vascular endothelial growth factor gene via an adenovirus vector. GenVec licenses the VEGF gene from Scios. A second study in peripheral vascular disease with BioByPass will follow soon after the first study.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth